Dr. Michael Haller is a pediatric endocrinologist with a passion for patient care, teaching, and research. He is currently Professor and Chief of Pediatric Endocrinology at the University of Florida (UF) College of Medicine, where he coordinates an active research team focused on the prediction, prevention, and reversal of type 1 diabetes (T1D).

He is an investigator in the NIH-funded Type 1 Diabetes TrialNet, NIH TEDDY Study, and T1D Exchange. He serves as Principal Investigator (PI) of the UF TrialNet Clinical Center, Chair of the Clinical Implementation Committee for the TEDDY Study, and Vice-President of the Florida Camp for Children and Youth with Diabetes. He was the PI of “first in man” studies aimed at using autologous umbilical cord blood stem cells as a potential therapy for T1D, and led a groundbreaking pilot study demonstrating the efficacy of Thymogloublin in patients with new onset and established T1D. He has also led several national studies using diabetes technologies, including inhaled insulin and insulin pumps/continuous glucose monitors.

Dr. Haller has published >200 peer-reviewed manuscripts and book chapters; in the last five years, he received over $10 million in research funding. He received the UF Douglas Barrett Award, Pediatric Endocrine Society Clinical Scholar Award, and JDRF Early Career Award. In 2008, Dr. Haller and his colleagues, Drs. Desmond Schatz and Mark Atkinson received the JDRF’s highest award, the Mary Tyler Moore and S. Robert Levine Excellence in Clinical Research Award, for their team approach to developing therapies for T1D. In 2023, Dr. Haller received the UF College of Medicine's Most Outstanding Clinical Researcher Award and the American Academy of Pediatrics Advocacy Award. In 2025, he received the UF College of Medicine's Most Outstanding Mentor Award. He currently sits in the Silverstein Family Eminent Scholar Chair in support of his work in pediatric T1D.